What's new

Human medicines European public assessment report (EPAR): Ambrisentan Viatris (previously Ambrisentan Mylan), ambrisentan, Date of authorisation: 20/06/2019, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Ambrisentan Viatris (previously Ambrisentan Mylan), ambrisentan, Date of authorisation: 20/06/2019, Revision: 7, Status: Authorised

Feb 14, 2025 - 11:06
 0
Human medicines European public assessment report (EPAR): Ambrisentan Viatris (previously Ambrisentan Mylan), ambrisentan, Date of authorisation: 20/06/2019, Revision: 7, Status: Authorised
Human medicines European public assessment report (EPAR): Ambrisentan Viatris (previously Ambrisentan Mylan), ambrisentan, Date of authorisation: 20/06/2019, Revision: 7, Status: Authorised
Read More

Tags:

Previous Article

Unilever : bénéfice 2024 pénalisé par la sortie de Russie et sa restructuration

Next Article

High-entropy alloy catalysts for advanced hydrogen-production zinc-based batteries

Related Posts

Human medicines European public assessment report (EPAR): Spexotras, trametinib, Date of authorisation: 05/01/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 18, 2025  0

Appendix 1: Acceptable intakes established for N-nitros...

Feb 9, 2025  0

Pre-authorisation guidance

Pre-authorisation guidance

Feb 24, 2025  0